Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
8217(c) 8109(c) 8066(c) 7920(c) 7858 Last
1 574 038 1 165 416 882 002 1 410 226 353 794 Volume
+1.19% -1.31% -0.53% -1.81% -0.78% Change
More quotes
Financials (USD)
Sales 2020 26 717 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 172 M - -
P/E ratio 2020 47,6x
Yield 2020 2,71%
Sales 2021 30 226 M - -
Net income 2021 4 530 M - -
Net Debt 2021 11 302 M - -
P/E ratio 2021 32,9x
Yield 2021 2,74%
Capitalization 136 B 137 B -
EV / Sales 2020 5,60x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - oncology (36.8%); - respiratory diseases (22.9%); - cardiovascular, renal and metabolic diseases (18.6%); - other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases. Net sales are distributed geographically as follows: the United... 
Sector
Pharmaceuticals
Calendar
10/22 | 10:00amPresentation
More about the company
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
05:45aCovid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
DJ
12:20aBritain partners with Oxford firm to assess coronavirus vaccine T cell respon..
RE
10/21ASTRAZENECA : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in ..
DJ
10/21ASTRAZENECA : Operation Warp Speed Chief Slaoui Expects U.S. Trials Of Vaccines ..
RE
10/21Ecuador signs COVID-19 vaccine supply deals with pharma companies
RE
10/21ASTRAZENECA : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in ..
DJ
10/21ASTRAZENECA : Deceased Astrazeneca Trial Volunteer Didn't Receive The Vaccine So..
RE
10/21AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue
RE
10/21Brazil's Bolsonaro rejects plan to buy China's Sinovac vaccine; health minist..
RE
10/21ASTRAZENECA : advances leadership in renal disease with more than 80 abstracts a..
AQ
10/21SANOFI : EU signs supply deal with J&J on potential COVID-19 vaccine
RE
10/21Australia shares rise on lift from financial, energy stocks
RE
10/21GSK to launch late-stage testing of syncytial virus vaccine
RE
10/20Australian shares gain on renewed U.S. stimulus hopes
RE
10/20EXCLUSIVE : U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - so..
RE
More news
News in other languages on ASTRAZENECA PLC
04:20aLA MINUTE DURABLE : Ce trio français champion sur le climat
04:14aLONDON STOCK EXCHANGE : Londres ouvre de nouveau en baisse
03:04aEN DIRECT DES MARCHES : Atos, Eurofins, Hermès, Pernod Ricard, STMicro, Thales, ..
03:02aLa peur du reconfinement
02:57aSTOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,20 $
Last Close Price 103,98 $
Spread / Highest target 49,5%
Spread / Average Target 13,7%
Spread / Lowest Target -36,5%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC4.11%136 586
JOHNSON & JOHNSON-1.33%378 942
ROCHE HOLDING AG-4.73%283 006
PFIZER INC.-4.31%206 049
MERCK & CO., INC.-14.16%197 458
NOVARTIS AG-16.89%186 106